On August 14, 2026, a new study involving MOTS-c was published in the journal Bioactive Materials. The publication is titled "Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming." The paper is indexed under PubMed ID 42633281.
This entry reflects the appearance of the publication in the scientific literature. MOTS-c remains classified as an unapproved research compound. No dosing information, clinical outcomes, or efficacy claims are included in this brief beyond confirming that the study has been published.
Readers interested in the broader context of MOTS-c research can consult the compound overview for additional background.